Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Earthwise Advertising & Investor Awareness Campaign September 1, 2025 RCM to Acquire Webbs Consol Silver Project from Lode Res. September 1, 2025 Commencement of Henbury Field Program September 1, 2025
